FTC Challenges Illumina’s Planned Acquisition of Liquid-Biopsy Firm Grail

  • 📰 WSJ
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 63%

United States News News

United States United States Latest News,United States United States Headlines

The FTC sued to block Illumina’s $7.1 billion deal for Grail, a major test in challenging a vertical merger in which companies don’t compete directly

WASHINGTON—The Federal Trade Commission filed a lawsuit Tuesday that seeks to block Illumina Inc.’sof a developer of a long-sought blood test that promises to detect cancer early.

The case sets up a major test for U.S. antitrust enforcement because Illumina’s proposed acquisition of Grail Inc. is a vertical merger of companies that don’t compete head-to-head. Most merger lawsuits involve challenges to so-called horizontal deals that involve the combination of direct rivals. There has only been one litigated challenge to a vertical merger in more than 40 years: the Justice Department’s 2017 case

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Total bull-shit. Vertical organization too? In the name of competition! Illumina started this venture, Grail and own 15% of it. Just let other pioneers to R &D new tests for cancer then discriminate this genuine business acquisition.

And yet they let Google, Amazon and Facebook buy whoever they want!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in US

United States United States Latest News, United States United States Headlines